commercial pharma deals , page-9

Conclusions: This trial supports a previously published IV administration study and provides further evidence that short term Cpn10 therapy is well tolerated and beneficial in treatment of active RA despite MTX therapy. Cpn10 treatment was associated with significant reductions in clinical measures of RA and circulating levels of biomarkers. Future trials are planned to determine the optimal dose range and route of administration to maximize efficacy.